Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14236021 | 0.82 | PLA2G10 (0.44) | HCAR3HCAR2MAPK1CHEK1RET | |
| SCHEMBL14235484 | 0.79 | ALPL (0.46) | HCAR3HCAR2MAPK1CHEK1RET | |
| SCHEMBL14235828 | 0.77 | ALPL (0.51) | HCAR3HCAR2MAPK1CHEK1RET | |
| SCHEMBL23682715 | 0.77 | HCAR3 (0.39) | HCAR3HCAR2MAPK1CHEK1RET | |
| SCHEMBL14235610 | 0.76 | MEN1 (0.55) | RAB9ANPC1NR1I2SMN1; SMN2MAPT | |
| SCHEMBL14236024 | 0.75 | ADORA3 (0.46) | HCAR3HCAR2CHEK1RETPDGFRB | |
| SCHEMBL14235370 | 0.74 | HCAR3 (0.47) | HCAR3HCAR2MAPK1RAB9AGAA | |
| SCHEMBL14236020 | 0.74 | MAPK8 (0.57) | MAPK14RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14235380 | 0.74 | ALPL (0.48) | RAB9ANPC1SMN1; SMN2GAAALPL | |
| SCHEMBL14236019 | 0.73 | MLLT1 (0.55) | RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | HCAR3 1923/4885HCAR2 2972/4885MAPK1 2499/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | HCAR3 2708/4885HCAR2 3496/4885MAPK1 3930/4885 |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | CYFIP2, TPX2, CYFIP1 | HCAR3 1528/4885HCAR2 1089/4885MAPK1 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.